Published in Medical Letter on the CDC and FDA, September 12th, 2004
Exactly what those warnings will say, and which drugs will be affected, hasn't been settled, according to FDA documents recently released. The agency will take the debate to its scientific advisers next month for help in deciding.
"While there remains a signal of risk ... for some drugs in some trials, it is important to note that the data are not black-and-white in providing a clear and definitive answer," FDA psychiatric drugs chief...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.